• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·AFIB
Share

Acutus Medical, Inc. Stocks

$ 0Last Updated 27.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

$ 2991

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Acutus Medical, Inc. is a company dedicated to the treatment of cardiac arrhythmias, focusing on the design, manufacturing, and commercialization of specialized tools for catheter-based ablation procedures. These solutions are utilized to manage a spectrum of heart rhythm disorders across both domestic U.S. and international markets. The firm's extensive product offerings include innovative access sheaths, transseptal crossing devices, diagnostic and mapping catheters, along with both traditional and contact-force ablation catheters. It also provides advanced mapping and imaging consoles, accompanying accessories, and vital supporting algorithms and software. Acutus Medical, Inc. was established in 2011 and is headquartered in Carlsbad, California.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

29.10.2026 01:34

Microsoft Beat Forecasts for Cloud Revenue

29.10.2026 01:17

"The Moment of Truth": Alphabet Shares Plunge 10% After Disappointing Earnings Report

29.10.2026 01:07

The U.S. Federal Reserve will reduce the number of interest rate meetings starting in 2027

29.10.2026 00:35

Is this the end of the “Magnificent Seven”? Big Tech stocks have diverged in their performance. Which ones should you choose?

29.10.2026 00:10

Oracle surprised the market with its cash flow forecast. Its shares soared 12%.

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026